Search results for "Liver cirrhosis."

showing 10 items of 598 documents

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

2012

Hepatitis C virus (HCV) is the leading cause of liver transplantation in Europe and is associated with an increased risk of hepatocellular carcinoma (HCC). Because of the chronic nature of the disease, estimates suggest that the burden on healthcare will increase dramatically for this entity. Clinical care of patients with HCV-related liver disease has advanced considerably in the last two decades, thanks to increasing knowledge about the mechanisms of the disease, development of diagnostic procedures, and advances in therapeutic and preventive approaches. HCV RNA testing, HCV genotyping and staging of liver disease are essential for the diagnosis and the management of HCV therapy. Furtherm…

Liver CirrhosisOncologymedicine.medical_specialtyGenotypemedicine.medical_treatmentHepatitis C virusHepacivirusDiseaseLiver transplantationmedicine.disease_causeAntiviral AgentsPolyethylene GlycolsLiver diseasechemistry.chemical_compoundPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesStandard of CareHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical PracticechemistryHepatocellular carcinomaPractice Guidelines as TopicImmunologyRNA ViralDrug Therapy Combinationbusinessmedicine.drugLiver International
researchProduct

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

2020

© 2020 The Author(s).

Liver CirrhosisPROGNOSISCirrhosisSCORING SYSTEM[SDV]Life Sciences [q-bio]PROGRESSIONDiseaseBiomarker Cirrhosis NAFLD NASHSTEATOHEPATITISDEFINITIONSCohort Studies0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePharmacology (medical)030212 general & internal medicineLongitudinal StudiesRegistriesComputingMilieux_MISCELLANEOUSmedia_commonPharmacology. TherapyFatty liverLiver NeoplasmsNASHGeneral Medicine3. Good healthCirrhosisLiver317 PharmacyCohort0305 other medical scienceCohort studymedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAGeriatrikQUESTIONNAIRENAFLD; NASH; Cirrhosis; Biomarker610 Medicine & health03 medical and health sciencesNAFLDmedicineSTEATOSISmedia_common.cataloged_instanceHumansALGORITHMEuropean unionIntensive care medicine030505 public healthbusiness.industryCONSUMPTIONBiomarkerSTAGING SYSTEMmedicine.diseaseDiabetes Mellitus Type 2Geriatrics3121 General medicine internal medicine and other clinical medicine3111 BiomedicineHuman medicineSteatohepatitisbusinessBiomarker; Cirrhosis; NAFLD; NASH
researchProduct

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.

1994

Hepatocellular carcinoma is one of the most common human cancers with an annual incidence of about 1,000,000 cases worldwide. Although hepatocellular carcinoma is predominant in hepatitis B virus endemic areas, it has also become a major problem in Europe, Japan and North America in close association with the increasing incidence of hepatitis C virus infection. The pathogenetic role of hepatitis C virus infection in the development of HBsAg-negative hepatocellular carcinoma needs to be clarified. In this paper the case of a 66-year-old HBsAg-negative and anti-HCV positive female who developed hepatocellular carcinoma in a cirrhotic liver is reported. After 1 year of follow up, urgent laparo…

Liver CirrhosisPathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusHepacivirusOvaryHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologyVirusMetastasisFlaviviridaeInternal medicinemedicineHumansAgedHepatitis B virusOvarian NeoplasmsHepatitis B Surface AntigensHepatologybiologyIncidenceLiver Neoplasmsmedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureHepatocellular carcinomaRNA ViralFemaleTomography X-Ray ComputedJournal of hepatology
researchProduct

Evolving therapies for liver fibrosis

2013

Fibrosis is an intrinsic response to chronic injury, maintaining organ integrity when extensive necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward excessive scarring and organ failure, as in liver cirrhosis. To date, antifibrotic treatment of fibrosis represents an unconquered area for drug development, with enormous potential but also high risks. Preclinical research has yielded numerous targets for antifibrotic agents, some of which have entered early-phase clinical studies, but progress has been hampered due to the relative lack of sensitive and specific biomarkers to measure fibrosis progression or reversal. Here we focus on antifibrotic approaches for li…

Liver CirrhosisPathologymedicine.medical_specialtyCirrhosisT-LymphocytesInflammationApoptosisBioinformaticsMonocytesMiceFibrosismedicineHepatic Stellate CellsAnimalsHumansMyofibroblastsInflammationWound Healingbusiness.industryLiver DiseasesMacrophagesStem CellsReview SeriesGeneral Medicinemedicine.diseaseFibrosisClinical trialDrug developmentLiverHepatic stellate cellDisease ProgressionHepatocytesStem cellmedicine.symptombusinessWound healingBiomarkers
researchProduct

Cirrhosis: CT and MR imaging evaluation

2006

In this article, we present the CT and MR imaging characteristics of the cirrhotic liver. We describe the altered liver morphology in different forms of viral, alcoholic and autoimmune end-stage liver disease. We present the spectrum of imaging findings in portal hypertension, such as splenomegaly, ascites and varices. We describe the patchy and lacelike patterns of fibrosis, along with the focal confluent form. The process of hepatocarcinogenesis is detailed, from regenerative to dysplastic nodules to overt hepatocellular carcinoma. Different types of non-neoplastic focal liver lesions occurring in the cirrhotic liver are discussed, including arterially enhancing nodules, hemangiomas and p…

Liver CirrhosisPathologymedicine.medical_specialtyCirrhosisbusiness.industryGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingLiver diseaseLiverHepatocellular carcinomaPractice Guidelines as TopicAscitesBudd–Chiari syndromemedicineHumansPortal hypertensionCongenital hepatic fibrosisRadiology Nuclear Medicine and imagingRadiologyPractice Patterns Physicians'medicine.symptomTomography X-Ray ComputedbusinessHepatic fibrosisEuropean Journal of Radiology
researchProduct

De novo expression of nonhepatocellular cytokeratins in Mallory body formation.

1998

Mallory bodies (MBs) are eosinophilic cytoplasmic inclusions observed predominantly in alcoholic liver disease. Although linked to disease activity, their pathogenesis is still unclear. Since intermediate filaments (cytokeratins) are major components of MBs, their cytokeratin polypeptide composition was analysed with monospecific antibodies for cytokeratins 7, 8, 14, 18, 19, and 20 by immunohistology. MBs were identified by light microscopy and ubiquitin immunostaining. All MBs were positive for cytokeratins 8 and 18. A significant percentage of the MBs was strongly positive for cytokeratins 19 and/or 20, which are not detectable in hepatocytes of normal liver and, in the case of cytokerati…

Liver CirrhosisPathologymedicine.medical_specialtyanimal structuresCarcinoma HepatocellularCytoplasmic inclusionmacromolecular substancesBiologyPathology and Forensic MedicineCytokeratinHepatolenticular DegenerationmedicineMallory bodyHumansIntermediate filamentChildMolecular BiologyLiver Diseases AlcoholicInclusion BodiesLiver DiseasesLiver NeoplasmsAntibodies MonoclonalCell BiologyGeneral Medicinemedicine.diseaseImmunohistochemistryStainingLiverImmunohistochemistryKeratinsEctopic expressionImmunostainingVirchows Archiv : an international journal of pathology
researchProduct

Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats

2020

BACKGROUND AND AIMS Portal hypertension is the main consequence of cirrhosis, responsible for the complications defining clinical decompensation. The only cure for decompensated cirrhosis is liver transplantation, but it is a limited resource and opens the possibility of regenerative therapy. We investigated the potential of primary human amniotic membrane-derived mesenchymal stromal (hAMSCs) and epithelial (hAECs) stem cells for the treatment of portal hypertension and decompensated cirrhosis. METHODS In vitro: Primary liver sinusoidal endothelial cells (LSECs) and hepatic stellate cells (HSCs) from cirrhotic rats (chronic CCl4 inhalation) were co-cultured with hAMSCs, hAECs or vehicle for…

Liver CirrhosisPathologymedicine.medical_specialtyhAECCirrhosisplacentaPortal venous pressure03 medical and health sciences0302 clinical medicineHypertension PortalSettore BIO/13 - BIOLOGIA APPLICATAAnimalsHumansMedicineAmnion610 Medicine & healthHepatologymedicine.diagnostic_testbusiness.industryMicrocirculationStem Cellschronic liver diseaseportal hypertensionEndothelial CellsAmniotic stem cellsmedicine.diseaseRatsLiver030220 oncology & carcinogenesisHepatic stellate cellPortal hypertensionVascular Resistance030211 gastroenterology & hepatologyStem cellbusinessHepatic fibrosisLiver function testshAMSCLiver International
researchProduct

Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression

2021

Abstract Background The universal treatment of diagnosed patients with chronic HCV infection has been widely conducted in Italy since 2017. However, the pool of individuals diagnosed but yet to be treated in Italy has been estimated to end around 2025, leaving a significant proportion of infected individuals undiagnosed/without care. Estimates of this population are currently unknown. Methods A probabilistic modelling approach was applied to estimate annual historical HCV incident cases by their age-group (0–100 years) distribution from available literature and Italian National database (1952 to October 2019). Viraemic infection rates were modelled on the main infection routes in Italy: peo…

Liver CirrhosisPediatricsBlood transfusionEpidemiologymedicine.medical_treatmentlaw.invention0302 clinical medicineFibrosislawEpidemiologyPrevalence030212 general & internal medicineStage (cooking)ChildSubstance Abuse IntravenousMonte CarloAged 80 and overeducation.field_of_studyMiddle AgedHepatitis CInfectious DiseasesTransmission (mechanics)ItalyChild PreschoolHCVmedicine.symptomModels Theoretical: Young AdultHumanAdultmedicine.medical_specialtySexual transmissionAdolescentLiver Cirrhosi030231 tropical medicinePopulationMarkov chainAntiviral AgentsMicrobiologyAsymptomaticlcsh:Infectious and parasitic diseasesYoung Adult03 medical and health sciencesVirologymedicineHumanslcsh:RC109-216Hepatitis C infectioneducationAgedAntiviral Agentbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornUndiagnosedInfantModels Theoreticalmedicine.diseaseParasitologybusiness
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct